Skip to content
The Policy VaultThe Policy Vault

adalimumab products — Medica

Scleritis

Initial criteria

  • age > 18 years
  • Patient has tried one other therapy for this condition (e.g., oral NSAIDs such as indomethacin, naproxen, or ibuprofen; oral, topical, or intravenous corticosteroids such as prednisone, prednisolone, methylprednisolone; methotrexate; cyclosporine; or other immunosuppressants)
  • Medication is prescribed by or in consultation with an ophthalmologist

Reauthorization criteria

  • Patient has been established on therapy for at least 6 months
  • Patient meets at least one of the following: (a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (examples: serum markers such as C-reactive protein, erythrocyte sedimentation rate); OR (b) Compared with baseline, patient experienced improvement in at least one symptom (e.g., decreased eye pain, redness, light sensitivity, tearing, and/or improvement in visual acuity)

Approval duration

Initial: 6 months; Reauth: 1 year